Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions
Tirzepatide is the most direct comparison, operating as a dual GIP/GLP-1 receptor agonist
H.SteinD
Collect the effluent of the target peak (using a small amount of pure product produced at the laboratory level under the same conditions as a reference to indicate the target peak), concentrate and freeze-dry to obtain the finished product, and obtain a total of 0.69g (MW: 1419.6) of the finished product
Sourcing quality products Product quality represents a significant concern in the peptide market
US$ 22.29
US$ 25.38
US$ 20.12
US$ 26.70
US$ 28.08